

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: October 4, 2010

Signature: Lynn L. Janulis/53,066
(Lynn L. Janulis)

Docket No.: 30572/42052
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Andreas Greinacher et al.

Application No.: 10/578,452

Confirmation No.: 2103

Filed: March 15, 2007

Art Unit: 1618

For: Use of MRP4-Inhibitors for the Treatment and/or
Prophylaxis of Cardiovascular Diseases

Examiner: S. V. Gembeh

AMENDMENT IN REPLY TO NON-FINAL OFFICE ACTION **MAILED JUNE 4, 2010**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

This paper is submitted in reply to a non-final Office Action mailed June 4, 2010 (hereinafter, the "Office Action") by the U.S. Patent and Trademark Office in the above-referenced application. Reconsideration of the application is respectfully requested in light of the following amendment and remarks. This reply is timely filed with a petition for an extension of time and the requisite fee. No additional fee is believed necessary in connection with the filing of this paper, but if a fee is necessary, the Commissioner is authorized to charge such fee to Marshall, Gerstein & Borun LLP deposit account number 13-2855.

Please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 7 of this paper.